drugset / Trial / NCT05189444

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

NCT05189444

RandomizedParallel-groupOpen-labelTreatment

Summary

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aim of this prospective study is to investigate the efficacy of Triple Therapy with Vonoprazan, Amoxicillin, and Bismuth for eradication of Hp, compared with standard quadruple therapy.

Timeline

Start
2022-03-25
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 0.75 g
Comparator Amoxicillin Other / unclassified 1 g
Comparator Clarithromycin Small molecule 0.5 g
Comparator Esomeprazole Small molecule 20 mg
Subject Vonoprazan Other / unclassified 20 mg
Background Bismuth Potassium Citrate Unknown 0.22 g